Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03667716 · ClinicalTrials.gov registry record · Phase 1
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
A Phase 1 study, sponsored by Compugen.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT03667716: Completed Phase 1 study, sponsored by Compugen.
NCT03667716 is a Phase 1 study that has completed, run by Compugen. The registered enrollment target is 121 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (102% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03667716, a Phase 1 study, has completed, sponsored by Compugen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
Primary Outcome
To evaluate the safety profile of COM701 monotherapy and in combination with nivolumab.
Interventions
- DRUG COM701
- DRUG COM701 with Opdivo (Nivolumab).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 1 |
What the finished NCT03667716 record still lists
NCT03667716 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (102% higher).
The record links to 0 conditions, and to 2 interventions - of which COM701 is the first listed.
NCT03667716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03667716 about?
NCT03667716 is a clinical study titled "COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.". This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
What is the current status of trial NCT03667716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2018-09-06. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT03667716?
The interventions under investigation include: COM701 (DRUG), COM701 with Opdivo (Nivolumab). (DRUG).
Who is sponsoring clinical trial NCT03667716?
This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03667716's enrollment target sits among peer trials
121 476th of 2000 higher than 1,522 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI